Resources with keywords: MPOX
Autochthonous clade Ib transmission confirmed in EU/EEA. Outside Africa, 97% of cases are male, 89% MSM — pattern relevant to clinical triage and ED screening protocols. Laboratory personnel should note that standard dermatopathology laboratory procedures (formalin fixation) adequately inactivate orthopoxviruses; however, unfixed specimens require BSL-2 handling. ECDC recommends JYNNEOS post-exposure prophylaxis for HCWs with unprotected exposure within 4 days.
HCWs caring for mpox patients without adequate PPE (gown, gloves, eye protection, N95 for aerosol-generating procedures) face direct contact transmission risk. All clades (Ia, Ib, IIb) circulating globally. Clade Ib recombinant with Ia/IIb genomic elements detected in February 2026; biological behavior not yet fully characterized. Diagnostic laboratory personnel handling skin lesion specimens must use BSL-2 enhanced precautions. JYNNEOS vaccine recommended for HCWs at occupational risk.
The UK Health Security Agency (UKHSA) has identified a new recombinant mpox virus in England in an individual who had recently travelled to Asia. Genomic sequencing showed that the mpox genome contained elements of clade Ib and IIb mpox.
Health authorities in Southern California have reported three cases of clade 1 monkeypox in people with no recent travel.
This dashboard provides data about COVID-19, flu, RSV and mpox virus levels in wastewater.
On November 18, 2024, the U.S. Centers for Disease Control and Prevention (CDC) issued a Health Alert Network (HAN) Health Advisory about the first case of clade I mpox diagnosed in the United States.
A vaccine consisting of modified vaccinia Ankara-Bavarian Nordic (MVA-BN), a live, attenuated, non-replicating, proprietary version of the MVA virus, used for the prevention of smallpox and monkeypox
The high proportion of children with suspected mpox reported in the current outbreak is likely due to a number of factors, including spread within and between close households, younger population demographics in impacted countries, misdiagnosis of other diseases (such as measles), poor sanitary conditions, limited access to health services, and a high level of food insecurity and malnutrition.
MVA-BN® (Modified Vaccinia Ankara – Bavarian Nordic) is a proprietary and patented vaccine platform technology of Bavarian Nordic.
Gigante CM, Takakuwa J, McGrath D, et al.
Tecovirimat is the first-line drug for treatment of orthopoxvirus infection (e.g., smallpox and mpox). Viral mutations that render the drug ineffective can develop during treatment.
